Jazz Pharmaceuticals, Inc. (JAZZ) Misses Q1 EPS by 18c; Guides FY In-Line

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q1 EPS of $1.61, $0.18 worse than the analyst estimate of $1.79. Revenue for the quarter came in at $247 million versus the consensus estimate of $254.86 million.

Jazz Pharmaceuticals, Inc. sees FY2014 EPS of $8.00-$8.25, versus the consensus of $8.2. Jazz Pharmaceuticals, Inc. sees FY2014 revenue of $1.1-1.16 billion, versus the consensus of $1.13 billion.

"We are pleased with the progress made during the first quarter, highlighted by the completion of two transactions that have positioned us well for both near- and long-term growth," said Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "We initiated the launch of Defitelio in Europe and are making significant progress in advancing late-stage projects in our development portfolio while also delivering continued growth of our key marketed products."

For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• Macatawa Bank (MCBC) Misses Q1 EPS by 1c